Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Study of Oral MRT-2359 in Selected Cancer Patients

Study ID: NCT05546268
Start Date: 2022-10-12
End Date: 2027-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

174

Intervention / Treatment

Oral MRT-2359

Oral MRT-2359

Oral MRT-2359

Oral MRT-2359

Oral MRT-2359

Oral MRT-2359

Sponsor

Monte Rosa Therapeutics, Inc

Source: clinicaltrials.gov

Share:
Add to list

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Study ID: NCT06408168
Start Date: 2024-08-08
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

58

Intervention / Treatment

Fulvestrant

Repotrectinib

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Researching the Effect of Exercise on Cancer

Study ID: NCT04589468
Start Date: 2020-10-02
End Date: 2025-10-02
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

70

Intervention / Treatment

Exercise

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors

Study ID: NCT05712668
Start Date: 2022-05-09
End Date: 2025-05
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Preoperative counseling

Asynchronous telemedicine

Sponsor

Carilion Clinic

Source: clinicaltrials.gov

Share:
Add to list

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Study ID: NCT06182072
Start Date: 2023-09-14
End Date: 2028-06-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

28

Intervention / Treatment

ProAgio Dose Levels (DL) 1,2,3,4

Gemcitabine, nab paclitaxel

Sponsor

ProDa BioTech, LLC

Source: clinicaltrials.gov

Share:
Add to list

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Study ID: NCT06794268
Start Date: 2025-02-04
End Date: 2044-08-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

Lisocabtagene maraleucel

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Source: clinicaltrials.gov

Share:
Add to list

The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)

Study ID: NCT06412172
Start Date: 2024-04-15
End Date: 2030-04-15
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment
Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Study ID: NCT05639972
Start Date: 2025-03-25
End Date: 2026-10-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

15

Intervention / Treatment

E7 TCR-T cells

Aldesleukin

Sponsor

Christian Hinrichs

Source: clinicaltrials.gov

Share:
Add to list

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

Study ID: NCT04453072
Start Date: 2020-07-01
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Interview

Media Intervention

Administration questionnaire

Scale Device

Telephone-Based Intervention

Text Message

Sponsor

Jonsson Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Study ID: NCT04265872
Start Date: 2020-10-15
End Date: 2026-03-31
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

20

Intervention / Treatment

Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis

Sponsor

Baylor Research Institute

Source: clinicaltrials.gov

Share:
Add to list